Hanke Mab
Latest round
- Series A
Last raised
- Aug 2023
Total raised
- Undisclosed
Investors
- 4
About Hanke Mab
Established in 2013 and based in Hefei, China, Hanke Mab is a biopharmaceutical company that focuses on the development and production of new genetically engineered antibody drugs. The company is a holding company of Anke Bioengineering (Group). The company received clinical approval for the HK001 program in 2020 and the HK003 program in 2021. It has partnerships with the University of Science and Technology of China, the Cancer Hospital of the Chinese Academy of Medical Sciences, Anhui University, and Anhui Medical University. The company's main business is the development of new genetically engineered antibody drugs. It also has three core platform technologies including AI-Computer Aided Design Platform, ISETbody Dual Antibody Construction Platform, and SCAPE Drug Screening Platform. In addition, it also provides a platform for phage antibody demonstration, bispecific antibody development, antibody durability research, and immunoassay kit development.
Who invested in Hanke Mab
4 investors across 1 round
See all investors in Hanke Mab
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Aug 21, 2023
Amount
Undisclosed
Investors
Questions about Hanke Mab
Who invested in Hanke Mab?
Hanke Mab has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hanke Mab raised?
Hanke Mab has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Hanke Mab last raise money?
Hanke Mab's most recent round on record is a Series A, in Aug 2023.
What does Hanke Mab do?
Established in 2013 and based in Hefei, China, Hanke Mab is a biopharmaceutical company that focuses on the development and production of new genetically engineered antibody drugs.
Where is Hanke Mab headquartered?
Hanke Mab is headquartered in Hefei, China.
Which VCs invest in companies like Hanke Mab?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Hanke Mab's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Hanke Mab? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.